Actively Recruiting
Evaluating Enlicitide Decanoate Compared to Placebo to Lower Bad Cholesterol in Adults With Hyperlipidemia in India
Led by Merck Sharp & Dohme LLC · Updated on 2026-11-02
150
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new treatments for high cholesterol, specifically focusing on lowering low-density lipoprotein cholesterol LDL-C, sometimes called bad cholesterol. This study evaluates enlicitide decanoate MK-0616, a medicine designed to reduce LDL-C. The goal is to determine if enlicitide is more effective than a placebo in lowering LDL-C levels and to assess its safety and tolerability in adults with hyperlipidemia. Participants will be randomly assigned to receive either 20 mg of enlicitide decanoate or a placebo orally once daily for up to 24 weeks. This phase 3, double-blind study compares the effects of the study medicine against placebo. The study focuses on treatment and monitors participants throughout the 24-week period while maintaining stable doses of any other lipid-lowering therapies. During the trial, participants will undergo evaluations at baseline and at week 24 to measure changes in LDL-C and other cholesterol markers such as non-HDL cholesterol, apolipoprotein B, and lipoprotein a. Researchers will also track adverse events and any discontinuations due to side effects throughout the study. The primary outcome is the mean percent change in LDL-C after 24 weeks, with safety monitored up to approximately 32 weeks from baseline.
CONDITIONS
Brief Title
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here